Kelun-Biotech Achieves IND Approval for Innovative SKB103 Bispecific ADC to Treat Solid Tumors Kelun-Biotech announces IND approval for SKB103, an innovative bispecific antibody-drug conjugate, paving the way for advanced cancer treatment.

Kelun-Biotech Achieves IND Approval for Innovative SKB103 Bispecific ADC to Treat Solid Tumors #China #Chengdu #ADC #Kelun-Biotech #SKB103